Cochlear Corp.'s ABI Provides Sound Perception In 82% Of NF2 Patients
This article was originally published in The Gray Sheet
Executive Summary
Labeling for Cochlear Corporation's Nucleus 24 auditory brainstem implant (ABI) should indicate that 82% of Neurofibromatosis Type 2 (NF2) patients implanted with the device perceived sound after having bilateral tumors removed from the auditory nerves.